Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Core Viewpoint - Windtree Therapeutics, Inc. reported significant progress in its clinical studies and financial results for Q3 2024, highlighting advancements in its istaroxime therapy for cardiogenic shock and ongoing efforts to secure funding for future developments [2][3]. Financial Results - For Q3 2024, the company reported an operating loss of $4.7 million, consistent with the same period in 2023 [9]. - Research and development expenses were $2.0 million, slightly down from $2.1 million in Q3 2023, primarily related to the SEISMiC Extension trial [10]. - General and administrative expenses increased to $2.8 million from $2.6 million in Q3 2023 [11]. - The net loss attributable to common stockholders was $3.8 million ($4.23 per basic share), an improvement from a net loss of $4.4 million ($15.47 per basic share) in Q3 2023 [12]. Clinical Developments - The SEISMiC B study demonstrated significant improvements in cardiac function and blood pressure in heart failure patients with early cardiogenic shock, meeting its primary endpoint [3][6]. - The company initiated the SEISMiC C study to further evaluate istaroxime in SCAI Stage C cardiogenic shock, aiming to transition to Phase 3 trials [6]. Capital and Funding - Windtree completed two private placements in July 2024, raising approximately $13.9 million, which included $4.4 million in new funding [4]. - An equity line of credit was established, allowing the company to sell up to $35 million of newly issued shares [5]. Patent Developments - The company expanded its patent estate with new patents for istaroxime in cardiogenic shock and acute heart failure, including filings in major markets such as the U.S., Japan, and China [7][8].